ATCC 2023 Holiday Shipping Schedule: We will be closed from December 22nd to January 1st. To ensure timely delivery, please submit orders in accordance with the following: Domestic orders no later than December 15th for shipment by December 20th 2023; International orders no later than December 12th for shipment by the first week of January 2024. We will resume our normal shipping schedule on January 2nd, 2024. Thank you for your cooperation.
BRCA1 analysis revealed that the cell line is homozygous for the BRCA1 5382C mutation, whereas the lymphoblastoid cell line derived from the same patient is heterozygous for the same mutation
The cell line has an acquired mutation of TP53 with wild-type allele loss; an acquired homozygous deletion of the PTEN gene, and loss of heterozygosity at multiple loci known to be involved in the pathogenesis of breast cancer
The cells are negative for expression of estrogen receptor (ER) and progesterone receptor (PR)
An EBV transformed lymphoblastoid cell line (HCC1937BL) from the same patient is available as ATCC CRL-2337
This cell line was deposited by Dr. A. Gazdar and is provided for research purposes only. This material is subject to the following restrictions in addition to those outlined in the ATCC Material Transfer Agreement:
The University of Texas Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, Texas 75235
Telephone: (214) 648-1888
Email: [email protected]
Tomlinson GE, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation. Cancer Res. 58: 3237-3242, 1998. PubMed: 9699648
Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771